Wedbush Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $63
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Wedbush analyst Laura Chico maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and lowers the price target from $64 to $63.
Wedbush analyst Laura Chico maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and lowers the price target from $64 to $63.